Huang, Qin

Jiang, Chunping

Wu, Youmin

Xia, Qiang

Gastroenterology Research and Practice

Harvard University - DASH 

 Novel Molecular Targets in Malignant Diseases of DigestiveSystem  (Article begins on next page)The Harvard community has made this article openly available.Please share how this access benefits you. Your story matters.Citation Jiang, Chunping, Youmin Wu, Qiang Xia, and Qin Huang. 2013.“Novel Molecular Targets in Malignant Diseases of DigestiveSystem.” Gastroenterology Research and Practice 2013 (1):568280. doi:10.1155/2013/568280.http://dx.doi.org/10.1155/2013/568280.Published Version doi:10.1155/2013/568280Accessed February 19, 2015 3:12:35 PM ESTCitable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879575Terms of Use This article was downloaded from Harvard University's DASHrepository, and is made available under the terms and conditionsapplicable to Other Posted Material, as set forth athttp://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAAHindawi Publishing CorporationGastroenterology Research and PracticeVolume 2013, Article ID 568280, 2 pageshttp://dx.doi.org/10.1155/2013/568280EditorialNovel Molecular Targets in Malignant Diseases ofDigestive SystemChunping Jiang,1 Youmin Wu,2 Qiang Xia,3 and Qin Huang41 Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University,Nanjing, Jiangsu 210008, China2Intra-Abdominal Transplant and Hepatobiliary Surgery, Westchester Medical Center of New York Medical College,Valhalla, NY 10595, USA3Department of Transplantation and Hepatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University,Shanghai 200127, China4H a r v a r dM e d i c a lS c h o o l ,B o s t o n ,M A0 2 1 3 2 ,U S ACorrespondence should be addressed to Chunping Jiang; chunpingjiang@163.comReceived 15 December 2013; Accepted 15 December 2013Copyright © 2013 Chunping Jiang et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Digestive malignancies remain one of the leading causes ofcancer-related death worldwide despite the fact that increas-ingclinicalandbiologicalknowledgehasemerged.Amongallthenewlydiscoveredcancercases,colorectalcancer,stomachcancer, liver cancer, and esophagus cancer rank in the frontand the mortality rate for them also tops the list. The poorprognosisofdigestivetumorsispartiallyduetolatediagnosis,delayed initiation of treatment, and unsatisfactory reactionto cancer therapies. Many molecular markers have been dis-c o v e r e df o re a r l yd i a g n o s i sa n db e t t e rt h e r a p e u t i co u t c o m e sfrom which we do benefit a lot. However, diagnosis andtreatmentofalimentarycancersrequirefurtheroptimization.We believe further study of novel molecular targets for earlydetection and better treatment would be helpful to reducemortality rate and to improve the prognosis of malignantdiseases of digestive system.In this current issue, we focus on recent advances inthe research of novel molecular targets which would helprevealthepossiblemechanismoftumorigenesis,progression,metastasis, and recurrence of digestive malignancies. Thepotential value of these molecular targets in cancer therapyis also highlighted. We present 10 articles on novel moleculartargets in digestive system of which six articles discuss themolecularmarkersinhepatocellularcarcinoma,threearticlesdiscuss the molecular makers in gastric carcinoma, and onem a k e sac o m p r e h e n s i v er e v i e wo no n ea n t i c a n c e rt a r g e ti ndigestive system cancer therapy.In the paper entitled “H-Ras oncogene expression andangiogenesis in experimental liver cirrhosis,” by G. ¨ O. Elpeket al. evaluated the relation between H-Ras expression andangiogenesisinlivercirrhosiswhichcanprogresstolivercar-cinoma.TheoncogeneH-Rasiselevatedinlivercirrhosisandcorrelates significantly with angiogenesis.“LEPREL1 expression in human hepatocellular carci-noma and its suppressor role on cell proliferation”by J. Wanget al. found that LEPREL1 was downregulated in hepatocel-lular carcinoma (HCC) tissues both in mRNA and proteinlevels, and the down-regulation was not associated withconventional clinical parameters of HCC. LEPREL1 couldserveasapotentialtumorsuppressorgenebyinhibitingHCCcell proliferation.The research paper “Expression of potential cancer stemcell marker ABCG2 is associated with malignant behaviorsof hepatocellular carcinoma” by G. Zhang et al. found thatABCG2 could probably function as a liver cancer stem cellmarker because of its close relationship with tumorigenesisand also because it could promote cell proliferation, drugresistance, and metastasis. This molecule may represent anattractive target for the innovation of cancer stem cell-directed therapy for HCC.In “Study of RNA interference targeting NET-1 combi-nation with sorafenib for hepatocellular carcinoma therapyin vitro and in vivo,” S. He et al. found that the interferenceof NET-1 could enhance the anticancer effect of sorafenib.2 Gastroenterology Research and PracticeThe interference of NET-1 could lead to impaired ability ofproliferation and migration and could induce apoptosis inH C Cc e l ll i n e .N E T - 1m a yb eap r o m i s i n gm o l e c u l a rt a r g e tto develop adjuvant therapy in combination with the onlyeffective targeted drug, sorafenib for HCC.Another two articles talked about the function of mic-roRNA in HCC. X.-Y. Huang et al. showed that miR-29 wasu p r e g u l a t e di nH C Ca n dc o r r e l a t e dw i t hp o o ro u t c o m e so fHCC. It might function by promoting cell proliferation andinhibiting cell apoptosis. The work by Z. Wang et al. clarifiedthe association of miR-499 and miR-34b/c polymorphismswith susceptibility to HCC and got to the final conclusionthatrs3746444wasnotassociatedwithsusceptibilitytoHCCwhile rs4938723 was associated with increased HCC risk.“Mastcellspositivetotryptaseandc-kitreceptorexpress-ing cells correlates with angiogenesis in gastric cancer pa-tients surgically treated” by M. Ammendola et al. studiedthe angiogenesis in gastric cancer and found that MCTP andc-kitR-EC correlated positively with microvascular density.Drugs against c-kitR and tryptase could be promising agentsin antiangiogenic therapy.“Significance of glutathione peroxidase 1 and caudal-re-latedhomeodomaintranscriptionfactorinhumangastricad-enocarcinoma,”J.J.Hanetal.demonstratedGPX1andCDX2might participate in the carcinogenesis, differentiation, andprogression of gastric adenocarcinoma, and CDX2 might bean independent prognostic factor.“Indirect comparison showed survival benefit from adju-vant chemoradiotherapy in completely resected gastric can-c e rw i t hD 2l y m p h a d e n e c t o m y ”b yQ .Y a n ge ta l .c o n fi r m e dthe role of adjuvant chemoradiotherapy in D2-resected gas-tric cancer patients with discussion of underlying molecularm e c h a n i s mo ft h i sb e n e fi t .Th er e v i e wa r t i c l e“ P P 2 A - m e d i a t e da n t i c a n c e rt h e r a p y ”by W. Chen et al. made a general review of the tumor sup-pressorPP2AbyfocusingonPP2Astructureandthepossiblemechanism of its participation in anticancer therapy.In summary, this special issue presents several intriguingachievements in the field of novel molecular targets in diges-tive malignancies which we hope could be utilized in the fu-ture for early diagnosis and treatment.AcknowledgmentsWewishtoexpressourappreciationtoalltheauthorsfortheirexcellent contribution and to the editors for their hard workon this issue.Chunping JiangYoumin WuQiang XiaQin Huang

Novel Molecular Targets in Malignant Diseases of Digestive System

Chunping Jiang

Youmin Wu

Qiang Xia

Qin Huang

Directory of Open Access Journals

Crossref

Hindawi Publishing CorporationGastroenterology Research and PracticeVolume 2013, Article ID 568280, 2 pageshttp://dx.doi.org/10.1155/2013/568280EditorialNovel Molecular Targets in Malignant Diseases ofDigestive SystemChunping Jiang,1 Youmin Wu,2 Qiang Xia,3 and Qin Huang41 Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University,Nanjing, Jiangsu 210008, China2 Intra-Abdominal Transplant and Hepatobiliary Surgery, Westchester Medical Center of New York Medical College,Valhalla, NY 10595, USA3Department of Transplantation and Hepatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University,Shanghai 200127, China4Harvard Medical School, Boston, MA 02132, USACorrespondence should be addressed to Chunping Jiang; chunpingjiang@163.comReceived 15 December 2013; Accepted 15 December 2013Copyright © 2013 Chunping Jiang et al.This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Digestive malignancies remain one of the leading causes ofcancer-related death worldwide despite the fact that increas-ing clinical and biological knowledge has emerged. Among allthe newly discovered cancer cases, colorectal cancer, stomachcancer, liver cancer, and esophagus cancer rank in the frontand the mortality rate for them also tops the list. The poorprognosis of digestive tumors is partially due to late diagnosis,delayed initiation of treatment, and unsatisfactory reactionto cancer therapies. Many molecular markers have been dis-covered for early diagnosis and better therapeutic outcomesfrom which we do benefit a lot. However, diagnosis andtreatment of alimentary cancers require further optimization.We believe further study of novel molecular targets for earlydetection and better treatment would be helpful to reducemortality rate and to improve the prognosis of malignantdiseases of digestive system.In this current issue, we focus on recent advances inthe research of novel molecular targets which would helpreveal the possiblemechanism of tumorigenesis, progression,metastasis, and recurrence of digestive malignancies. Thepotential value of these molecular targets in cancer therapyis also highlighted. We present 10 articles on novel moleculartargets in digestive system of which six articles discuss themolecularmarkers in hepatocellular carcinoma, three articlesdiscuss the molecular makers in gastric carcinoma, and onemakes a comprehensive review on one anticancer target indigestive system cancer therapy.In the paper entitled “H-Ras oncogene expression andangiogenesis in experimental liver cirrhosis,” by G. O¨. Elpeket al. evaluated the relation between H-Ras expression andangiogenesis in liver cirrhosis which can progress to liver car-cinoma.The oncogeneH-Ras is elevated in liver cirrhosis andcorrelates significantly with angiogenesis.“LEPREL1 expression in human hepatocellular carci-noma and its suppressor role on cell proliferation” by J. Wanget al. found that LEPREL1 was downregulated in hepatocel-lular carcinoma (HCC) tissues both in mRNA and proteinlevels, and the down-regulation was not associated withconventional clinical parameters of HCC. LEPREL1 couldserve as a potential tumor suppressor gene by inhibitingHCCcell proliferation.The research paper “Expression of potential cancer stemcell marker ABCG2 is associated with malignant behaviorsof hepatocellular carcinoma” by G. Zhang et al. found thatABCG2 could probably function as a liver cancer stem cellmarker because of its close relationship with tumorigenesisand also because it could promote cell proliferation, drugresistance, and metastasis. This molecule may represent anattractive target for the innovation of cancer stem cell-directed therapy for HCC.In “Study of RNA interference targeting NET-1 combi-nation with sorafenib for hepatocellular carcinoma therapyin vitro and in vivo,” S. He et al. found that the interferenceof NET-1 could enhance the anticancer effect of sorafenib.2 Gastroenterology Research and PracticeThe interference of NET-1 could lead to impaired ability ofproliferation and migration and could induce apoptosis inHCC cell line. NET-1 may be a promising molecular targetto develop adjuvant therapy in combination with the onlyeffective targeted drug, sorafenib for HCC.Another two articles talked about the function of mic-roRNA in HCC. X.-Y. Huang et al. showed that miR-29 wasupregulated in HCC and correlated with poor outcomes ofHCC. It might function by promoting cell proliferation andinhibiting cell apoptosis. The work by Z. Wang et al. clarifiedthe association of miR-499 and miR-34b/c polymorphismswith susceptibility to HCC and got to the final conclusionthat rs3746444 was not associated with susceptibility to HCCwhile rs4938723 was associated with increased HCC risk.“Mast cells positive to tryptase and c-kit receptor express-ing cells correlates with angiogenesis in gastric cancer pa-tients surgically treated” by M. Ammendola et al. studiedthe angiogenesis in gastric cancer and found that MCTP andc-kitR-EC correlated positively with microvascular density.Drugs against c-kitR and tryptase could be promising agentsin antiangiogenic therapy.“Significance of glutathione peroxidase 1 and caudal-re-lated homeodomain transcription factor in human gastric ad-enocarcinoma,” J. J. Han et al. demonstrated GPX1 and CDX2might participate in the carcinogenesis, differentiation, andprogression of gastric adenocarcinoma, and CDX2 might bean independent prognostic factor.“Indirect comparison showed survival benefit from adju-vant chemoradiotherapy in completely resected gastric can-cer with D2 lymphadenectomy” by Q. Yang et al. confirmedthe role of adjuvant chemoradiotherapy in D2-resected gas-tric cancer patients with discussion of underlying molecularmechanism of this benefit.The review article “PP2A-mediated anticancer therapy”by W. Chen et al. made a general review of the tumor sup-pressor PP2A by focusing on PP2A structure and the possiblemechanism of its participation in anticancer therapy.In summary, this special issue presents several intriguingachievements in the field of novel molecular targets in diges-tive malignancies which we hope could be utilized in the fu-ture for early diagnosis and treatment.AcknowledgmentsWewish to express our appreciation to all the authors for theirexcellent contribution and to the editors for their hard workon this issue.Chunping JiangYoumin WuQiang XiaQin HuangSubmit your manuscripts athttp://www.hindawi.comStem CellsInternationalHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014MEDIATORSINFLAMMATIONofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Behavioural NeurologyEndocrinologyInternational Journal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Disease MarkersHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014BioMed Research InternationalOncologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Oxidative Medicine and Cellular LongevityHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014PPAR ResearchThe Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014Immunology ResearchHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Journal ofObesityJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014 Computational and  Mathematical Methods in MedicineOphthalmologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Diabetes ResearchJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Research and TreatmentAIDSHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Gastroenterology Research and PracticeHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Parkinson’s DiseaseEvidence-Based Complementary and Alternative MedicineVolume 2014Hindawi Publishing Corporationhttp://www.hindawi.com

http://dash.harvard.edu/bitstream/handle/1/11879575/3881519.pdf?sequence=1

Novel Molecular Targets in Malignant Diseases of Digestive System

Abstract

Similar works

Full text

Available Versions

Harvard University - DASH

Directory of Open Access Journals

Crossref